Table 4.
Threshold analysis of interferon beta-1b treatment for secondary progressive multiple sclerosis (Tayside, 1993-5): values required to meet different costs per QALY thresholds
| Cost per QALY gained (£) | Yearly cost of interferon/patient (£) (% reduction from baseline) | Discounted QALYs gained per 18 people treated for 30 months (increase from baseline) | Costs saved per 9 months of wheelchair dependence avoided (£) (increase from baseline) | |
|---|---|---|---|---|
| Baseline | 1 024 393 | 9 600 (baseline) | 0.397 (baseline) | 2 840 (baseline) |
| Threshold 1 | 50 000 | 565 (94) | 8.2 (21-fold) | 389 975 (150-fold) |
| Threshold 2 | 30 000 | 379 (96) | 13.6 (34-fold) | 397 900 (153-fold) |
| Threshold 3 | 20 000 | 287 (97) | 20.3 (51-fold) | 402 000 (155-fold) |
| Threshold 4 | 10 000 | 194 (98) | 40.8 (103-fold) | 405 850 (156-fold) |